The Main Pharmaceutical Inspectorate withdrew from the market one batch of Euvax B and Tripacel vaccines each. Vaccines against jaundice as well as diphtheria, tetanus and pertussis were withdrawn due to the wrong consistency of the preparations.
Chief Pharmaceutical Inspector Zofia Ulz assured that parents of recently vaccinated children can rest assured – defective vaccines have not been given.
This quality defect consists in the change in the appearance of the vaccine and professional medical personnel, such as nurses, would never administer such a vaccine in their life – Ulz told PAP on Friday. She added that, firstly, the nurses know what the vaccine should look like, and secondly, the appearance of these preparations was so changed that they would not pass through the syringe needle.
This defect was reported by nurses, who noticed that the vaccine did not look as it should, secured it and reported it to the provincial inspectorate, where samples were taken and sent for examination – emphasized Ulz.
Yesterday we received the test results and withdrew the vaccines due to the inhomogeneity – she added.
She stressed that there is no possibility that this vaccine will be administered and that it is only one series of each of these vaccines.
The remaining series of products are safe and remain on the market.
Ulz added that the defective batches of vaccines were most likely poorly stored. Vaccines are particularly sensitive to temperature fluctuations, we suppose that the deterioration in quality occurred at some stage in the transport or storage of vaccines, she said.
Euvax B is a vaccine against hepatitis B. It is used, inter alia, in in newborns. Tripacel is a combined, cell-free vaccine against diphtheria, tetanus and pertussis. in infants.
Radio Zet was the first to announce the withdrawal of vaccines. (PAP)
js/ itm/ jbr/